Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1486 Views
-
Last post by NHE
-
- 0 Replies
- 825 Views
-
Last post by NHE
-
- 0 Replies
- 2348 Views
-
Last post by frodo
-
- 0 Replies
- 1109 Views
-
Last post by NHE
-
- 1 Replies
- 1086 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1379 Views
-
Last post by frodo
-
- 0 Replies
- 1578 Views
-
Last post by NHE
-
- 0 Replies
- 2117 Views
-
Last post by vesta
-
- 0 Replies
- 1636 Views
-
Last post by frodo